Insights
Insights From Our Experts
Articles
Function Over Fashion: Implementing Value-Based Contracts Successfully
Public outcry over drug pricing, increased government scrutiny, and proposed exceptions to government pricing rules propelled the healthcare industry to move from volume to value-based contracting models. Known alternatively as innovative outcomes or risk-based agreements, value-based…
PharmaVOICE Showcase on Connected Health and IoT
The Growing Potential of Connected IoT In PharmaVOICE’s Showcase on Connected Health and IoT, Ed Cox offers executive viewpoints on the challenges of integrating the Internet of Medical Things (IoMT) into pharma processes. “Breaking down siloes…
PharmaVOICE Outsourcing Showcase
The New Roaring 20s: How Outsourced Commercialization is the Revolution We Need. To effectively commercialize a product, traditional service silos stand in the way of true healthcare transformation. Do disparate service providers look at the life…
How COVID-19 Has Changed Payer Engagement Strategies
The healthcare industry is rightly focused on COVID-19 and its impact on patient care and allocation or utilization of healthcare resources. However, we cannot lose sight of our responsibility to provide appropriate therapeutic options for the…
What is Your Data Integration and Analytics Platform Strategy?
Posted on April 22, 20204/22/20
If I Could Only Ask Two Questions, the First One Would Be: What is Your Data Integration and Analytics Platform Strategy? It’s really simple, data analytics drives decisions. In the healthcare industry, we use data to…
Oncology Market: Outlook of Brand Access and Insights
The oncology market is constantly changing and EVERSANA continues to assess current and future market trends, payer willingness to pay and the optimal patient support services to ensure you have all the insights you need to…
What does the new FDA Guidance for DTx Products Treating Psychiatric Disorders actually mean?
On April 14, 2020, FDA posted new guidance that eases regulatory enforcement of Digital Therapeutics to improve patient access to psychiatric care during the COVID-19 public health emergency. FDA should be praised for this decision, as…
What kind of clinical data is required for FDA clearance of a Digital Medicine?
What kind of clinical data is required for FDA clearance of a Digital Medicine? It depends. Digital therapeutics and digital medicines that are subject to FDA regulation are considered medical devices. The amount of clinical data…
What specifically triggers FDA regulation of a digital medicine?
I often meet with Digital Health or Pharmaceutical clients to discuss their commercialization journey, and they ask me the same question. What specifically triggers FDA regulation of a digital medicine? Some of these products require FDA…
New Product Commercialization – Webinar
Posted by
Private: Tom Doyle on March 27, 20203/27/20
Q. How do you successfully commercialize a new product in the new era of “patient-as-consumer” and “outcomes-based healthcare”? A. You design and deliver an engaging, high-touch patient experience. In this 30 minute webinar, Tom Doyle explains…